Biotechnology Contract Manufacturing Market Size and Scope 2026 to 2035
Segmentation of Biotechnology Contract Manufacturing Market :
Biotechnology Contract Manufacturing Market By Service
- Manufacturing
- Formulation and Fill-Finish
- Packaging and Labeling
- Other services
Biotechnology Contract Manufacturing Market By Type
- Biologic Drug Substance Manufacturing
- Biologic Drug Product Manufacturing
Biotechnology Contract Manufacturing Market By Scale of Operation
- Commercial Operations
- Clinical Operations
Biotechnology Contract Manufacturing Market By Source
- Mammalian Expression Systems
- Non-Mammalian Expression Systems
Biotechnology Contract Manufacturing Market By Molecule
- Monoclonal Antibodies
- Cell Therapy & Gene Therapy
- Antibody-Drug Conjugates (ADCs)
- Vaccines
- Therapeutic Peptides & Proteins
- Other Molecule Types
Biotechnology Contract Manufacturing Market By Therapeutic Area
- Oncology
- Autoimmune Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Infectious Diseases
- Neurology
- Other Therapeutic Areas
Biotechnology Contract Manufacturing Market By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biotechnology Contract Manufacturing Market Snapshot
Chapter 4. Global Biotechnology Contract Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Service Estimates & Trend Analysis
5.1. By Service, & Market Share, 2024-2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Service:
5.2.1. Manufacturing
5.2.2. Formulation and Fill-Finish
5.2.3. Packaging and Labeling
5.2.4. Other services
Chapter 6. Market Segmentation 2: By Type Estimates & Trend Analysis
6.1. By Type & Market Share, 2024-2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type:
6.2.1. Biologic Drug Substance Manufacturing
6.2.2. Biologic Drug Product Manufacturing
Chapter 7. Market Segmentation 3: By Scale of Operation Estimates & Trend Analysis
7.1. By Scale of Operation & Market Share, 2024-2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Scale of Operation:
7.2.1. Commercial Operations
7.2.2. Clinical Operations
Chapter 8. Market Segmentation 4: By Source Estimates & Trend Analysis
8.1. By Source & Market Share, 2024-2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Source:
8.2.1. Mammalian Expression Systems
8.2.2. Non-Mammalian Expression Systems
Chapter 9. Market Segmentation 5: By Molecule Estimates & Trend Analysis
9.1. By Molecule & Market Share, 2024-2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Molecule:
9.2.1. Monoclonal Antibodies
9.2.2. Cell Therapy & Gene Therapy
9.2.3. Antibody-Drug Conjugates (ADCs)
9.2.4. Vaccines
9.2.5. Therapeutic Peptides & Proteins
9.2.6. Other Molecule Types
Chapter 10. Market Segmentation 6: By Therapeutic Area Estimates & Trend Analysis
10.1. By Therapeutic Area & Market Share, 2024-2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Therapeutic Area:
10.2.1. Oncology
10.2.2. Autoimmune Diseases
10.2.3. Cardiovascular Diseases
10.2.4. Metabolic Diseases
10.2.5. Infectious Diseases
10.2.6. Neurology
10.2.7. Other Therapeutic Areas
Chapter 11. Biotechnology Contract Manufacturing Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Service, 2021-2034
11.1.2. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Type, 2021-2034
11.1.3. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034
11.1.4. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Source, 2021-2034
11.1.5. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Molecule, 2021-2034
11.1.6. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
11.1.7. North America Biotechnology Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
11.2. Europe
11.2.1. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Service, 2021-2034
11.2.2. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Type, 2021-2034
11.2.3. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034
11.2.4. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Source, 2021-2034
11.2.5. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Molecule, 2021-2034
11.2.6. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) By Therapeutic Area, 2021-2034
11.2.7. Europe Biotechnology Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034
11.3. Asia Pacific
11.3.1. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Service, 2021-2034
11.3.2. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Type, 2021-2034
11.3.3. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034
11.3.4. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Source, 2021-2034
11.3.5. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Molecule, 2021-2034
11.3.6. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) By Therapeutic Area, 2021-2034
11.3.7. Asia Pacific Biotechnology Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034
11.4. Latin America
11.4.1. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Service, (US$ Million) 2021-2034
11.4.2. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Type, (US$ Million) 2021-2034
11.4.3. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
11.4.4. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Source, (US$ Million) 2021-2034
11.4.5. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034
11.4.6. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
11.4.7. Latin America Biotechnology Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034
11.5. Middle East & Africa
11.5.1. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Service, (US$ Million) 2021-2034
11.5.2. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Type, (US$ Million) 2021-2034
11.5.3. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
11.5.4. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Source, (US$ Million) 2021-2034
11.5.5. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034
11.5.6. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
11.5.7. Middle East & Africa Biotechnology Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1 Lonza (Switzerland)
12.2.2 Samsung Biologics (South Korea)
12.2.3 Thermo Fisher Scientific, Inc. (US)
12.2.4 Catalent, Inc. (US)
12.2.5 JSR Corporation (Japan)
12.2.6 WuXi Biologics (China)
12.2.7 AbbVie, Inc. (US)
12.2.8 Boehringer Ingelheim International GmbH (Germany)
12.2.9 Eurofins Scientific (Luxembourg)
12.2.10 GenScript Biotech Corporation (US)
12.2.11 AGC, Inc. (Japan)
12.2.12 FUJIFILM Holding Corporation (Japan)
12.2.13 Merck KgaA (Germany)
12.2.14 Stelis
12.2.15 Recipharm Ab
12.2.16 Emergent
12.2.17 Shanghai Fosun Pharmaceutical Co., Ltd.
12.2.18 Lotte Biologics
12.2.19 Hepalink Group
12.2.20 Curia Global, Inc.
12.2.21 Jrs Pharma
12.2.22 Minapharm Pharmaceuticals
12.2.23 Rentschler Biopharma Se
12.2.24 Avid Bioservices, Inc.
12.2.25 Abzena Ltd.
12.2.26 Polyplus Transfection
12.2.27 Midas Pharma GMBH
12.2.28 Mabplex International Co., Ltd.
12.2.29 Asahi Kasei Corporation
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Biotechnology Contract Manufacturing Market Size is valued at USD 20.5 Bn in 2024 and is predicted to reach USD 46.6 Bn by the year 2034
Biotechnology Contract Manufacturing Market is expected to grow at a 8.7% CAGR during the forecast period for 2025-2034.
Jrs Pharma, Minapharm Pharmaceuticals, Rentschler Biopharma Se, Avid Bioservices, Inc., Abzena Ltd., Polyplus Transfection, Midas Pharma GMBH, Mabplex
Biotechnology Contract Manufacturing Market is segmented on the basis of service, type, scale of operation, source, molecule, and therapeutic area.
Asia Pacific region is leading the Biotechnology Contract Manufacturing Market.